Key result
Treatment with recombinant Angptl2 for 4 weeks in diabetic db/db mice decreased plasma glucose, insulin, and lipids, and increased adiponectin, improving glucose tolerance and insulin sensitivity.
Why the study?
Does recombinant Angptl2 improve insulin sensitivity and glucose tolerance in diabetic db/db mice and cultured adipocytes?
Population
Leptin receptor-deficient diabetic db/db mice with insulin resistance, C57BL/6J mice, high-fat-fed mice…
Design
Preclinical
Follow-up
4 weeks
Authors
Loading...
May inform Angptl2-targeted therapies in type 2 diabetes; leaves open translation from db/db mice to humans.
Does recombinant Angptl2 improve insulin sensitivity and glucose tolerance in diabetic db/db mice and cultured adipocytes?
Replenishment of Angptl2 stimulates insulin sensitivity and improves the type 2 diabetic state in preclinical mouse models.
Kitazawa et al. (2011) studied Type 2 Diabetes and Insulin Resistance. Recombinant Angptl2 was evaluated on Plasma glucose, insulin, triglyceride, fatty acid levels, and adiponectin expression. Treatment with recombinant Angptl2 for 4 weeks in diabetic db/db mice decreased plasma glucose, insulin, and lipids, and increased adiponectin, improving glucose tolerance and insulin sensitivity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: